【Medipal Holdings】2026 Financial Results｜Sales of ¥3.8 trillion, Net Income of ¥420 million

Performance Overview

For the fiscal year ending March 2026, consolidated sales increased by 4.0% YoY to ¥3.8173 trillion, and net income rose by 5.6% to ¥42.534 billion, maintaining steady growth. Segment-wise, revenue was primarily driven by the pharmaceutical wholesale business, with ongoing progress in overseas expansion and new drug research. Although operating income slightly declined, the company has established a stable earnings foundation overall. Moving forward, it will continue expanding and improving efficiency in line with its medium-term vision, aiming for sales of ¥3.9 trillion and net income of ¥3.9 billion in 2027.

Impact on Shareholders & Future Outlook

Dividends are scheduled to increase to ¥66 per share, continuing a prudent dividend policy in 2027. Based on its medium-term vision, the company aims for sustainable growth through overseas expansion, growth in preventive medicine and pre-disease sectors, and digital transformation. The consolidated earnings forecast for 2027 anticipates sales of ¥3.944 trillion (+3.3%) and net income of ¥39 million (-8.3%), with ongoing efforts to diversify and streamline its business.